US payment policy for medications to treat opioid use disorder: landscape and opportunities, in Health Affairs Scholar
key takeaway: "The experts interviewed cautioned against rigid reimbursement models that force patients into one-size-fits-all care and endorsed future development and adoption of value-based MOUD payment models. More than 70% of experts surveyed reported that Medicare, Medicaid, and private insurers should increase payment for office- and opioid treatment program–based MOUD. Validation of MOUD performance metrics is needed to support future value-based initiatives."
Comentários